Passage Bio Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Passage Bio Inc (PASG) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Passage Bio Inc vs Its Competitors
- Scale: Passage Bio Inc ranks #140 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 0.0% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Passage Bio Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Passage Bio Inc | - | - | - | Yes |
| Competitors combined (16) | ||||
| High-Confidence Competitors (14) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PASG Stock Performance relative to its Competitors
PASG Stock Performance relative to High-Confidence Competitors
PASG Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Contextlogic Inc | 282.9% | Outperformed |
| 2 | Alector Inc | 282.9% | Outperformed |
| 3 | Solid Biosciences Inc | 282.9% | Outperformed |
| 4 | Takeda Pharmaceutical Company Limited | 282.9% | Outperformed |
| 5 | Denali Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Passage Bio Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Passage Bio Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Passage Bio Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Passage Bio Inc |
11.01 | - |
 Gsk Plc |
212,190.18 | 43,093.89 |
 Takeda Pharmaceutical Company Limited |
33,856.26 | 30,079.37 |
 Crispr Therapeutics Ag |
4,840.92 | 25.17 |
 Denali Therapeutics Inc |
3,904.94 | 110.69 |
 Taysha Gene Therapies Inc |
1,612.72 | 8.10 |
| SUBTOTAL | 261,688.73 | 73,923.12 |
Sign in to see all competitors of Passage Bio Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Passage Bio Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Passage Bio Inc's Competitors Named by the Company
Competitive relationships identified from Passage Bio Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| uniQure N.V. | Company report | 85% |
| Denali Therapeutics | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Prevail Therapeutics Inc. | Company report | 85% |
| Alector, Inc. | Company report | 85% |
| Latus Bio, Inc. | Company report | 85% |
| Astellas Pharma Inc. | Company report | 85% |
| Crispr Therapeutics Ag | Company report | 85% |
| QurAlis Corporation | Company report | 85% |
| AviadoBio | Company report | 85% |
| Kyowa Kirin Co., Ltd. | Company report | 85% |
| Voyager Therapeutics, Inc. | Company report | 85% |
| Evox Therapeutics Ltd | Company report | 85% |
| Eli Lilly & Co | Company report | 85% |
| Astellas | Company report | 85% |
| Transposon Therapeutics, Inc. | Company report | 85% |
| QurAlis Therapeutics | Company report | 85% |
| Applied Genetic Technologies Corporation | Company report | 85% |
| Syncona Limited | Company report | 85% |
| Lysogene, S.A. | Company report | 85% |
| Orchard Therapeutics plc | Company report | 85% |
| National Institutes of Health | Company report | 85% |
| Forge Biologics Inc. | Company report | 85% |
| Neurogene Inc. | Company report | 85% |
| Shape Therapeutics Inc. | Company report | 85% |
| Sio Gene Therapies, Inc. | Company report | 85% |
| AcuraStem Inc. | Company report | 85% |
| Arkuda Therapeutics, Inc. | Company report | 85% |
| Alkermes plc | Company report | 85% |
| Medicines Co | Company report | 85% |
| Sangamo Therapeutics Inc | Company report | 85% |
| Solid Biosciences Inc | Company report | 85% |
| 4d Molecular Therapeutics Inc | Company report | 85% |
| Taysha Gene Therapies Inc | Company report | 85% |
| Bluebird Bio Inc | Company report | 85% |
| Contextlogic Inc | Company report | 85% |
| Editas Medicine Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Passage Bio Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Passage Bio Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Uniqure N v | Single Reportable Segment 100.00 % |
| Editas Medicine Inc | Reportable 100.00 % |
| Protalix Biotherapeutics inc | Single Reportable Segment 100.00 % |
| Voyager Therapeutics Inc | Single reportable segment 100.00 % |
| Sangamo Therapeutics Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Passage Bio Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Passage Bio Inc | 11 | - | -1,337,481 |
| Gsk Plc | 212,190 | 169,660,977 | 32,662,867 |
| Takeda Pharmaceutical Company Limited | 33,856 | 639,986 | 15,106 |
| Crispr Therapeutics Ag | 4,841 | 125,234 | -2,269,328 |
| Denali Therapeutics Inc | 3,905 | 220,068 | 393,668 |
| Taysha Gene Therapies Inc | 1,613 | 81,798 | -1,511,444 |
| PEERS TOTAL | 261,678 | 1,479,765 | 153,890 |
Passage Bio Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| 4d Molecular Therapeutics Inc | JP 97.05 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Passage Bio Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 158 companies in Passage Bio Inc's industry classification, broader than the peer set above. Market cap in millions of $.Passage Bio Inc ranks #140 of 158 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,338, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 253,085 | 25.70 % |
| 2 | Gilead Sciences Inc | 210,465 | 21.38 % |
| 3 | Moderna Inc | 107,062 | 10.87 % |
| 4 | Argenx Se | 63,538 | 6.45 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Mesoblast Limited | 1,234 | 5.2% |
| 9 | Exelixis Inc | 1,234 | 5.2% |
| 10 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 140 | Passage Bio Inc | 11 | 0.00 % |
Market cap and industry share for the rest of Passage Bio Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-09.
Passage Bio Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 135 | Jasper Therapeutics Inc | 16 | 760.11 % |
| 136 | Black Hawk Acquisition Corporation | 15 | - |
| 137 | Dyadic International Inc | 14 | -65.54 % |
| 138 | Genenta Science S p a | 12 | - |
| 139 | Pluri Inc | 1,234 | 12.3% |
| 140 | Passage Bio Inc | 11 | - |
| 141 | Biocardia Inc | 1,234 | 12.3% |
| 142 | Brainstorm Cell Therapeutics inc | 1,234 | 12.3% |
| 143 | Futuretech Ii Acquisition Corp | 1,234 | 12.3% |
| 144 | Intensity Therapeutics Inc | 1,234 | 12.3% |
| 145 | Senti Biosciences Holdings Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Passage Bio Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-09. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Passage Bio Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (159 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.5x | - |
| EV / EBITDA | - | 16.7x | - |
| P/B | 1.2x | 5.1x | -3.9x |
| Return on Equity | -218.59 % | industry aggregate | -217.05 % |
| Return on Invested Capital | -87.68 % | -10.87 % (avg) | -76.81 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Passage Bio Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| Return on Invested Capital | -16.18 % | -27.30 % | -27.59 % | -35.78 % | -37.65 % | -55.78 % |
| P/E | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Passage Bio Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Passage Bio Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.5% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Passage Bio Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,338 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Passage Bio Inc's dedicated Suppliers and Customers pages, not here.
Passage Bio Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Passage Bio Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Passage Bio Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 217.1 points below the industry aggregate.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (43.80 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-37.7% annualized).
Methodology: see Methodology: SWOT Analysis.
Passage Bio Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Passage Bio Inc | 1.82 | 1.90 | - |
| Gsk Plc | 0.16 | 0.82 | 0.87 |
| Takeda Pharmaceutical Company Limited | 0.15 | 1.01 | 0.58 |
| Crispr Therapeutics Ag | 2.24 | 16.26 | 0.25 |
| Denali Therapeutics Inc | 2.28 | 8.30 | - |
| Taysha Gene Therapies Inc | 13.32 | 13.51 | 0.19 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Passage Bio Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Passage Bio Inc | Q2 2026 | - | - |
| Gsk Plc | Q4 2025 | +7.5 % | +120.0 % |
| Takeda Pharmaceutical Company Limited | Q1 2025 | +1.8 % | -28.9 % |
| Crispr Therapeutics Ag | Q3 2026 | +1,325.1 % | - |
| Denali Therapeutics Inc | Q3 2026 | - | - |
| Taysha Gene Therapies Inc | Q2 2026 | - | - |
| PEERS TOTAL | +5.4 % | +115.6 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Passage Bio Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Passage Bio Inc | Q2 2026 | - | - |
| Gsk Plc | Q4 2025 | +7.2 % | -0.6 % |
| Takeda Pharmaceutical Company Limited | Q1 2025 | -8.7 % | +8.5 % |
| Crispr Therapeutics Ag | Q3 2026 | - | +459.5 % |
| Denali Therapeutics Inc | Q3 2026 | - | - |
| Taysha Gene Therapies Inc | Q2 2026 | - | - |
Passage Bio Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Passage Bio Inc | - | - | - |
| Gsk Plc | 10.09% | 44.94% | 38.67% |
| Takeda Pharmaceutical Company Limited | 0.75% | 0.97% | 1.53% |
| Crispr Therapeutics Ag | - | - | - |
| Denali Therapeutics Inc | 16.42% | 17.88% | 21.40% |
| Taysha Gene Therapies Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Passage Bio Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Passage Bio Inc | - | - |
| Gsk Plc | 37.13 | 4.92 |
| Takeda Pharmaceutical Company Limited | 0.31 | 1.13 |
| Crispr Therapeutics Ag | - | 192.31 |
| Denali Therapeutics Inc | - | 35.28 |
| Taysha Gene Therapies Inc | - | 199.15 |
| PEERS AVERAGE | 34.20 | 3.54 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.